Loading...
XKRX039200
Market cap630mUSD
Dec 26, Last price  
24,400.00KRW
1D
-0.61%
1Q
-28.84%
Jan 2017
239.86%
IPO
1,019.82%
Name

Oscotec Inc

Chart & Performance

D1W1MN
XKRX:039200 chart
P/E
—
P/S
186.40
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.03%
Rev. gr., 5y
-23.34%
Revenues
4.95b
-2.20%
24,755,850,12021,858,819,38017,110,321,00018,335,817,6103,553,891,3963,908,490,78018,702,671,5114,368,519,89943,470,793,3843,902,734,7525,062,376,4934,950,929,999
Net income
-24.28b
L-0.61%
-14,476,368,760-3,970,862,400-2,022,401,030395,029,229-3,645,623,319-5,856,532,8603,470,819,696-22,435,600,783-4,356,524,883-26,262,552,170-24,429,544,991-24,279,525,966
CFO
-22.05b
L-16.55%
3,335,386,500-1,345,620,790-1,962,080,260645,418,561-3,369,209,475-3,689,052,797-5,077,994,13027,468,801-17,881,396,374-8,761,867,982-26,420,974,927-22,047,670,110
Dividend
Dec 29, 200850 KRW/sh
Earnings
Mar 17, 2025

Profile

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
URL
http://www.oscotec.com/
IPO date
Jan 17, 2007
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,950,930
-2.20%
5,062,376
29.71%
3,902,735
-91.02%
Cost of revenue
30,794,190
29,624,330
28,179,467
Unusual Expense (Income)
NOPBT
(25,843,260)
(24,561,954)
(24,276,732)
NOPBT Margin
Operating Taxes
(3,793,758)
(209,316)
6,929
Tax Rate
NOPAT
(22,049,502)
(24,352,638)
(24,283,662)
Net income
(24,279,526)
-0.61%
(24,429,545)
-6.98%
(26,262,552)
502.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
117,355,087
334,549
BB yield
-21.19%
-0.03%
Debt
Debt current
24,530,017
9,765,632
6,476,410
Long-term debt
246,575
319,335
775,462
Deferred revenue
131,595
212,242
Other long-term liabilities
2,499,772
2,591,085
2,131,250
Net debt
(72,706,004)
(109,619,627)
(14,704,803)
Cash flow
Cash from operating activities
(22,047,670)
(26,420,975)
(8,761,868)
CAPEX
(581,220)
(1,249,155)
(10,344,654)
Cash from investing activities
13,379,143
(99,563,032)
7,175,527
Cash from financing activities
11,124,649
120,262,173
5,871,030
FCF
(20,956,603)
(20,259,576)
(22,997,633)
Balance
Cash
97,480,596
103,695,691
14,584,448
Long term investments
2,000
16,008,904
7,372,228
Excess cash
97,235,049
119,451,476
21,761,539
Stockholders' equity
(128,637,400)
(93,876,483)
(70,893,407)
Invested Capital
250,466,996
228,275,519
111,457,998
ROIC
ROCE
EV
Common stock shares outstanding
38,244
32,010
31,742
Price
23,050.00
33.24%
17,300.00
-50.53%
34,972.32
-44.21%
Market cap
881,528,372
59.19%
553,765,717
-50.12%
1,110,096,033
-42.05%
EV
804,722,008
444,039,002
1,097,814,681
EBITDA
(23,986,437)
(22,922,024)
(22,817,059)
EV/EBITDA
Interest
406,636
316,400
107,650
Interest/NOPBT